Chronic myelomonocytic leukemia (CMML) is a rare and complex blood cancer affecting primarily older adults, with a higher incidence in men. It combines features of two other blood cancer types: myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPN). While CMML currently lacks disease-modifying therapies, the landscape is rapidly changing with the development of novel treatments.
DelveInsight’s ‘Chronic Myelomonocytic Leukemia Pipeline Insight 2024’ report reveals a robust pipeline of 25+ therapies in various stages of clinical development. Over 22 pharmaceutical companies are actively working to transform the treatment paradigm for CMML patients. Key players include Kura Oncology, Immune-Onc Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, AbbVie, Nerviano Medical Sciences, Newave Pharmaceuticals, Amgen, and others.
The report identifies promising CMML pipeline therapies such as Tipifarnib, IO-202, Sabatolimab, Ruxolitinib, Venetoclax, NMS-03592088, LP-108, AMG-176, and more. These drugs are currently undergoing various phases of clinical trials, offering hope for improved treatment outcomes.
Recent updates in the CMML clinical trial landscape include:
*
July 2024:
The FDA placed a partial clinical hold on a Phase I trial evaluating Seclidemstat (SP-2577) for the treatment of MDS or CMML.*
June 2024:
Immune-Onc Therapeutics announced positive interim Phase Ib expansion cohort data for IO-202 in patients with CMML at the 2024 European Hematology Association (EHA) Annual Meeting.*
February 2024:
Immune-Onc Therapeutics received Orphan Drug Designation from the FDA for IO-202 for the treatment of CMML.*
January 2024:
Taiho Oncology published final results from the pivotal ASCERTAIN clinical trial of fixed-dose oral decitabine and cedazuridine (INQOVI®) compared to intravenous decitabine in adults with intermediate and high-risk MDS including CMML.*
April 2023:
Nerviano Medical Sciences presented data from the First-In-Human study of NMS-03592088, a novel inhibitor of FLT3, KIT, and CSF1R, at the American Association for Cancer Research 2023 Annual Meeting.The ‘Chronic Myelomonocytic Leukemia Pipeline Insight 2024’ report provides comprehensive information on the CMML clinical trial landscape, including detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage drugs, inactive and dormant assets, driving and restraining factors, and an assessment of opportunities and risks. The report also offers an overview of CMML, its characteristics, diagnosis, and treatment options, highlighting the need for effective therapies.
With ongoing research and clinical trials, the future of CMML treatment holds immense promise. The emergence of new therapies provides hope for improved outcomes and a better quality of life for patients battling this rare and challenging blood cancer.
